Levetiracetam API
IOL Chemicals and Pharmaceuticals Limited Expertise in Levetiracetam
IOLCP produces Levetiracetam in a dedicated block having a capacity around.
Highest quality standards that meet all Pharmacopeial and ICH requirements.
A very well control strategies put in place to show the absence of all potential mutagenic impurities.
Contact Us
Contact Us
IOL Chemicals and Pharmaceuticals Limited Expertise in Levetiracetam
IOLCP produces Levetiracetam in a dedicated block having a capacity around.
Highest quality standards that meet all Pharmacopeial and ICH requirements.
A very well control strategies put in place to show the absence of all potential mutagenic impurities.
Mechanism of Action
Levetiracetam modulates synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A in the brain.
SV2A is a membrane-bound protein that is found on synaptic vesicles and is ubiquitous throughout the CNS - it appears to play a role in vesicle exocytosis and in the modulation of synaptic transmission by increasing the available number of secretory vesicles available for neurotransmission.
Stimulation of pre-synaptic SV2A by levetiracetam may inhibit neurotransmitter release, but this action does not appear to affect normal neurotransmission, suggesting that action at this site contributes to the anti-epileptic activity of the drug.
Indication
The main therapeutic indications are:
Levetiracetam is used as an adjunctive therapy in the treatment of partial onset seizures in epileptic patients.
Download Our Brochure to Know More
Related Products
